Your search history is turned on.
Date: May 25, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan, Yukon
Microsoft Word - Notice of Change of Corporate Structure - Cardiome (00220434-2xDECAD).doc NATIONAL INSTRUMENT 51-102 Continuous Disclosure Obligations Notice of Change in Corporate Structure Section 4.9 1. Name of Parties to Transaction Cardiome Pharma Corp. (Cardiome) Correvio Pharma Corp. (Correvio) Cipher Pharmaceuticals Inc. (Ciphe...
Microsoft Word - Material Change Report for Cardiome (00224935-2xDECAD).doc Form 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Cardiome Pharma Corp. (Cardiome) 2345 Argentia Road Mississauga, Ontario L5N 8K4 2. Date of Material Change May 15, 2018. 3. News Release Correvio Pharma Corp. issued a news rele...
Microsoft Word - Early Warning Press Release (00220915-2xDECAD).docx Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp. MISSISSAUGA, ON, May 16, 2018 Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. (Cipher) of the Canadian business portfolio of Cardiome Pharma Corp. (Cardiome) w...
Microsoft Word - Early Warning Report (00220401-2xDECAD).doc Form 62-103F1 Required Disclosure under the Early Warning Requirements Item 1 Security and Reporting Issuer 1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities. This report relates to common ...
Date: May 17, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan, Yukon
Microsoft Word - CORV New Ticker Final.docx 1 Nasdaq: CORV TSX: CORV CORREVIO PHARMA CORP, FORMERLY CARDIOME PHARMA CORP, ANNOUNCES STOCK TICKER SYMBOL CHANGE TO CORV Vancouver, Canada, May 17, 2018 Correvio Pharma Corp. (Nasdaq:CORV / TSX:CORV), formerly Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company foc...
1 NASDAQ: CRME TSX: COM CORREVIO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 STUDY EVALUATING BRINAVESS IN CHINA Vancouver, Canada, May 17, 2018 Correvio Pharma Corp. (NASDAQ: CRME / TSX: COM), formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, d...
Date: May 15, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan, Yukon
_ Form 52-109F2 Certification of interim filings - full certificate I, William Hunter, President and Chief Executive Officer of Cardiome Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cardiome Pharma Corp. (the issuer) for the interim period ended Mar...
_ Form 52-109F2 Certification of interim filings - full certificate I, Justin Renz, Chief Financial Officer of Cardiome Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cardiome Pharma Corp. (the issuer) for the interim period ended March 31, 2018. ...
MANAGEMENT DISCUSSION & ANALAYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 1 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (MD&A) of Cardiome Pharma Corp. (Cardiome, we, us or our) for the three months ended March 31, 2018 is as of May 14, 2018. We h...
FINANCIAL STATEMENTS ...